Revenue: As of FY2026 Q2, the actual value is USD 0.

Revenue

HeartSciences reported no meaningful revenue for the second quarter of fiscal 2026.

Cash and Cash Equivalents

As of October 31, 2025, the company had approximately $2.0 million in cash and cash equivalents.

Shareholders’ Equity

The company had $4.2 million in shareholders’ equity as of October 31, 2025.

Outlook / Guidance

HeartSciences expects to announce key customer wins in the near term and plans to host an investor call early in the new year to demonstrate the MyoVista Insights software and provide additional details regarding its commercialization strategy and market opportunity.